From the Department of Neurology (M.D., H.-P.H., P.A.), Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany; and Brain and Mind Center (H.-P.H.), University of Sydney, Australia.
Neurol Neuroimmunol Neuroinflamm. 2021 Mar 2;8(3). doi: 10.1212/NXI.0000000000000976. Print 2021 May.
As an antagonist of voltage-gated potassium (Kv) channels, 4-aminopyridine (4-AP) is used as symptomatic therapy in several neurologic disorders. The improvement of visual function and motor skills and relieve of fatigue in patients with MS have been attributed to 4-AP. Its prolonged release formulation (fampridine) has been approved for the symptomatic treatment of walking disability in MS. The beneficial effects were explained by the blockade of axonal Kv channels, thereby enhancing conduction along demyelinated axons. However, an increasing body of evidence suggests that 4-AP may have additional properties beyond the symptomatic mode of action. In this review, we summarize preclinical and clinical data on possible neuroprotective features of 4-AP.
作为电压门控钾 (Kv) 通道的拮抗剂，4-氨基吡啶 (4-AP) 被用作几种神经疾病的对症治疗药物。4-AP 可改善 MS 患者的视觉功能和运动技能，并缓解疲劳。其长效释放制剂（fampridine）已被批准用于 MS 患者的步行障碍的对症治疗。其有益作用可以通过阻断轴突 Kv 通道来解释，从而增强脱髓鞘轴突的传导。然而，越来越多的证据表明，4-AP 可能具有除症状作用模式以外的其他特性。在这篇综述中，我们总结了 4-AP 可能具有神经保护作用的临床前和临床数据。
